Effect of vancomycin versus linezolid on hospital length of stay in patients with suspected or confirmed influenza and bacterial pneumonia

Carly E. Stoneman, Shauna D. Winters, Lauren L. Labeff, Robert Heidel, Leslie Hamilton

Research output: Contribution to journalArticle

Abstract

Introduction Patients with influenza who then present with bacterial pneumonia often present with methicillin-resistant Staphylococcus aureus pneumonia. There is a paucity of literature about how antibiotic choice affects length of stay in these patients. The objective of this study was to assess if vancomycin or linezolid affects hospital length of stay in patients with bacterial pneumonia complicating influenza. Methods This was a single-center, retrospective cohort study conducted at the University of Tennessee Medical Center in Knoxville, Tenn. Inclusion criteria were adults 18 years or older who were admitted to the hospital with suspected postinfluenza pneumonia. In addition, these patients either received 24 hours of oseltamivir or had a positive influenza screen and received at least 24 hours of vancomycin or linezolid for empiric coverage of methicillin-resistant S. aureus pneumonia. Results A total of 186 patients were included in the study. There was no difference in overall length of stay between the linezolid and vancomycin groups (P = 0.937). Secondary outcomes included intensive care unit (ICU) length of stay and in-hospital mortality. The group treated with vancomycin had increased in-hospital mortality (P = 0.043) and longer ICU length of stay (P = 0.048). Discussion Although there was no difference in hospital length of stay between the 2 treatment groups, the vancomycin group had a longer ICU length of stay and increased mortality when compared with the linezolid group.

Original languageEnglish (US)
Pages (from-to)28-31
Number of pages4
JournalInfectious Diseases in Clinical Practice
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Linezolid
Bacterial Pneumonia
Vancomycin
Human Influenza
Length of Stay
Intensive Care Units
Methicillin-Resistant Staphylococcus aureus
Hospital Mortality
Pneumonia
Staphylococcal Pneumonia
Oseltamivir

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Effect of vancomycin versus linezolid on hospital length of stay in patients with suspected or confirmed influenza and bacterial pneumonia. / Stoneman, Carly E.; Winters, Shauna D.; Labeff, Lauren L.; Heidel, Robert; Hamilton, Leslie.

In: Infectious Diseases in Clinical Practice, Vol. 27, No. 1, 01.01.2019, p. 28-31.

Research output: Contribution to journalArticle

@article{a4784540d590458c935bce25f5bfd714,
title = "Effect of vancomycin versus linezolid on hospital length of stay in patients with suspected or confirmed influenza and bacterial pneumonia",
abstract = "Introduction Patients with influenza who then present with bacterial pneumonia often present with methicillin-resistant Staphylococcus aureus pneumonia. There is a paucity of literature about how antibiotic choice affects length of stay in these patients. The objective of this study was to assess if vancomycin or linezolid affects hospital length of stay in patients with bacterial pneumonia complicating influenza. Methods This was a single-center, retrospective cohort study conducted at the University of Tennessee Medical Center in Knoxville, Tenn. Inclusion criteria were adults 18 years or older who were admitted to the hospital with suspected postinfluenza pneumonia. In addition, these patients either received 24 hours of oseltamivir or had a positive influenza screen and received at least 24 hours of vancomycin or linezolid for empiric coverage of methicillin-resistant S. aureus pneumonia. Results A total of 186 patients were included in the study. There was no difference in overall length of stay between the linezolid and vancomycin groups (P = 0.937). Secondary outcomes included intensive care unit (ICU) length of stay and in-hospital mortality. The group treated with vancomycin had increased in-hospital mortality (P = 0.043) and longer ICU length of stay (P = 0.048). Discussion Although there was no difference in hospital length of stay between the 2 treatment groups, the vancomycin group had a longer ICU length of stay and increased mortality when compared with the linezolid group.",
author = "Stoneman, {Carly E.} and Winters, {Shauna D.} and Labeff, {Lauren L.} and Robert Heidel and Leslie Hamilton",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/IPC.0000000000000692",
language = "English (US)",
volume = "27",
pages = "28--31",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of vancomycin versus linezolid on hospital length of stay in patients with suspected or confirmed influenza and bacterial pneumonia

AU - Stoneman, Carly E.

AU - Winters, Shauna D.

AU - Labeff, Lauren L.

AU - Heidel, Robert

AU - Hamilton, Leslie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction Patients with influenza who then present with bacterial pneumonia often present with methicillin-resistant Staphylococcus aureus pneumonia. There is a paucity of literature about how antibiotic choice affects length of stay in these patients. The objective of this study was to assess if vancomycin or linezolid affects hospital length of stay in patients with bacterial pneumonia complicating influenza. Methods This was a single-center, retrospective cohort study conducted at the University of Tennessee Medical Center in Knoxville, Tenn. Inclusion criteria were adults 18 years or older who were admitted to the hospital with suspected postinfluenza pneumonia. In addition, these patients either received 24 hours of oseltamivir or had a positive influenza screen and received at least 24 hours of vancomycin or linezolid for empiric coverage of methicillin-resistant S. aureus pneumonia. Results A total of 186 patients were included in the study. There was no difference in overall length of stay between the linezolid and vancomycin groups (P = 0.937). Secondary outcomes included intensive care unit (ICU) length of stay and in-hospital mortality. The group treated with vancomycin had increased in-hospital mortality (P = 0.043) and longer ICU length of stay (P = 0.048). Discussion Although there was no difference in hospital length of stay between the 2 treatment groups, the vancomycin group had a longer ICU length of stay and increased mortality when compared with the linezolid group.

AB - Introduction Patients with influenza who then present with bacterial pneumonia often present with methicillin-resistant Staphylococcus aureus pneumonia. There is a paucity of literature about how antibiotic choice affects length of stay in these patients. The objective of this study was to assess if vancomycin or linezolid affects hospital length of stay in patients with bacterial pneumonia complicating influenza. Methods This was a single-center, retrospective cohort study conducted at the University of Tennessee Medical Center in Knoxville, Tenn. Inclusion criteria were adults 18 years or older who were admitted to the hospital with suspected postinfluenza pneumonia. In addition, these patients either received 24 hours of oseltamivir or had a positive influenza screen and received at least 24 hours of vancomycin or linezolid for empiric coverage of methicillin-resistant S. aureus pneumonia. Results A total of 186 patients were included in the study. There was no difference in overall length of stay between the linezolid and vancomycin groups (P = 0.937). Secondary outcomes included intensive care unit (ICU) length of stay and in-hospital mortality. The group treated with vancomycin had increased in-hospital mortality (P = 0.043) and longer ICU length of stay (P = 0.048). Discussion Although there was no difference in hospital length of stay between the 2 treatment groups, the vancomycin group had a longer ICU length of stay and increased mortality when compared with the linezolid group.

UR - http://www.scopus.com/inward/record.url?scp=85059746873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059746873&partnerID=8YFLogxK

U2 - 10.1097/IPC.0000000000000692

DO - 10.1097/IPC.0000000000000692

M3 - Article

VL - 27

SP - 28

EP - 31

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 1

ER -